Printer Friendly

Better glycemic control with insulin premix 50/50 TID compared to insulin premix 70/30 BID/Premix 50/50 insulin ile premix 70/30 insuline kiyasla daha iyi glisemik kontrol mumkundur.


Type 2 diabetes mellitus is a progressive disease. Irrespective of therapeutic regimen, glycemic control deteriorates with time (1,2). Achieving the optimal glycemic treatment goals reduces long-term microvascular complications and delays the risk of macrovascular disease (3). Achievement and maintenance of tight glycemic control require titration of the therapy by initiating insulin when oral hypoglycemic agents fail to reduce A1C levels to the target. However, only a small proportion of people with type 2 diabetes mellitus actually are able to succeed in treatment goals and the number of patients requiring insulin therapy eventually rise (4-6). The results of a UK Prospective Diabetes Study (UKPDS) substudy and large observational PRESENT study revealed that initiation or early addition of insulin to oral therapy further improved the glycemic control in type 2 diabetic patients (3,7). The optimal insulin regimen in type 2 diabetes mellitus varies among physicians depending on the properties of the patients and guidelines released by diabetes federations. Although the choice of initial insulin regimen varies, biphasic insulins are the most prescribed insulin throughout the world (8). The ideal insulin treatment must mimic the endogenous physiological insulin profile. The most resembling model is basal-bolus insulin treatment. The results of the abovementioned studies indicate that compared to basal-bolus insulin treatment, insulin lispro premix 50/50 TID provided similar glycemic profile with better postprandial glycemic control but with worse fasting glycemia than basal-bolus treatment (9). Although there are some studies comparing human insulin premix 70/30 with insulin lispro premix 50/50 revealing better glycemia with the latter, there is no study comparing different premix analog insulins (10). The aim of this study was to compare the efficacy and safety of insulin lispro premix 50/50 with insulin aspart premix 70/30 in patients with type 2 diabetes mellitus.

Materials and Methods


Patients with type 2 diabetes mellitus aged 18-80 years started on insulin treatment due to poor glycemic control because of either inadequacy of oral agents or severe hyperglycemia (defined as fasting blood glucose above 200 mg/dl) on the admission were enrolled. The study population consisted of a total of 122 type 2 diabetic patients who were commenced on insulin treatment for the first time either with insulin lispro premix 50/50 three times daily (n=60) or insulin aspart premix 70/30 two times daily (n=62) at the outpatient clinic of endocrinology of Yeditepe University Hospital. Only those patients who were self monitoring their blood glucose at least 4 times in a week in a scheduled manner and patients whose A1C levels could be obtained at the start and end of the study period were included into the study. Patients who had end-stage diseases such as renal, hepatic or heart failure, active cancer treatment and were on steroid therapy were not included in the study.

Study Design

This was a single-centre, retrospective study conducted at Yeditepe University Hospital from January 2009 to June 2010 in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki. All study documentation was reviewed and approved by the Institutional Review Board.

Data collected from the electronic database of the hospital included demographic characteristics, medical history, physical examination findings, all laboratory measurements either done at Yeditepe University Hospital or other laboratories, if recorded and treatment recommendations in each visit. The patients were followed up in a scheduled manner every three months and the above data were recorded in each visit. At the start of treatment, all patients were strictly educated about the application of insulin, use of insulin delivery devices (insulin pens), proper measurement and recording of blood glucose, awareness and management of hypoglycemia and nutrition. The patients were encouraged to self-measure their blood glucose levels every single day of the week at 7-point (before and 2 hours after each main meal and at bedtime) or 4-point (before each main meal and at bedtime) profile and were asked to report their measurements weekly the day after it was done to either diabetes nurse or doctor. Communication was conducted via a direct phone call to diabetes nurse or, if preferred by the patient, via fax, e-mail, or short visit. At each visit, the patients were asked about compliance with insulin applications, meal planning, any hypoglycemia and its management, and all information gathered was recorded. The insulin dose titrations were done by the nurse or doctor. More than 80% of patients preferred the 4-point profile, but there was no difference in the compliance of patients in the whole group. Those patients with 80% or above measurements obtained were included into the study. The measurements were done by glucometers approved by the Ministry of Health of Turkey. Four different glucometers were used by the patients.


The primary objective was to determine whether greater improvements in glycemic control could be achieved with insulin lispro premix 50/50 TID compared to insulin aspart premix 70/30 BID. The secondary objective was to investigate the differences in fasting and postprandial blood glucose measurements, rate of improvement in A1C or blood glucose measurements, initial and mean insulin doses, incidence and rate of hypoglycemia.

Symptomatic hypoglycemia was defined as an event with symptoms consistent with hypoglycemia below 70 mg/dl. Severe hypoglycemia was the one, in which symptoms consistent with hypoglycemia required the assistance of another person. Nocturnal hypoglycemia was defined as symptoms of hypoglycemia occurring after the last insulin injection and before the morning insulin dose.

Laboratory Measurements

A1C levels were analyzed using turbidimetric inhibition immunological analysis (TINIA) (Tina-quant Hemoglobin A1c Gen.2, COBAS INTEGRA 400/800, Roche Diagnostics GmbH, Mannheim, Germany; normal reference range 4.8-5.9%) at the central laboratory of Yeditepe University Hospital.


Statistical data were analyzed by SPSS[R] 15.0 for Windows[R]. Descriptive statistics were provided for each variable including demographic, laboratory and self-monitored blood glucose measurements. Variables were not normally distributed as tested by the Kolmogorov-Smirnov test. Nonparametric tests were used. Results are shown as median (minimum-maximum). Comparisons between groups were done using the Mann-Whitney U test and Wilcoxon matched-pairs test as appropriate. For categorical variables [chi square]-based tests were used. The Spearman test was used for correlation analysis. For repeated measurements of blood glucose, the Friedman test was used. Statistical significance considered at p <0.05.


Demographic Data

Demographic characteristics of the study subjects are presented in Table 1. The patients in Group 1 were younger (p=0.005) and with shorter disease period (p=0.04) than the patients in Group 2. Fifty three percent of patients in Group 1 and 68% of patients in Group 2 were younger than 65 years. Elderly patients above the age of 70 years were equally distributed among the groups and constituted less than 10% of the study population. Eleven percent of patients in Group 1 and 20% in Group 2 had newly diagnosed diabetes.

Change in A1C level

Glycemic parameters are listed in Table 2. Median basal A1C level was found to be higher in Group 1 compared to Group 2 (p=0.002). There was no difference in the final A1C level between the groups (Figure 2), but the rate of improvement was greater in Group 1. The net decrease in A1C was 1.4% (-1.5% - 5.8%) in Group 1 and 0.7% (-1.0% - 4.2%) in Group 2 (p=0.0006) (Figure 3).

Target A1C

There was no difference in the number of patients achieving target A1C level (p=0,519). Thirty one percent (n=19) of patients in Group 1 and 25% (n=15) in Group 2 achieved the target A1C level of below 6.5%.

Blood Glucose Levels

Basal fasting blood glucose (FBG) levels were similar and improved during the study in both groups. The final mean FBG level was found to be significantly lower in patients using insulin aspart premix 70/30 compared to those using insulin lispro premix 50/50 (p=0,008).

Actual 2-h postprandial blood glucose measurements could not be obtained but instead, pre-meal blood glucose was measured and will be cited as PPG elsewhere in the text. The cumulative PPG was found to be significantly lower in the patients of Group 1 compared to group 2 patients (p<0.0001 (Figure 4). Four-point blood glucose measurements revealed better results in pre-lunch (p=0.007) and pre-supper (p=0.03) blood glucose values in favor of patients in Group 1. There was no statistically significant difference in midnight blood glucose measurements between the groups. Four-point measurements are shown in Figure 1.

Total Daily Insulin Dose

The total daily insulin dose administered was higher in both basal (p<0.0001) and at the end point (p=0.01) in patients using insulin lispro premix 50/50 compared to patients using insulin aspart premix 70/30 (Table 2). There was no statistically significant difference in the total daily dose of insulin during the study period "within the groups. Insulin therapy was initiated as three equal doses of the calculated total daily insulin, which was administered before each meal in Group 1, and 2/3 of the dose before breakfast and 1/3 of the dose before supper in Group 2. But at the end point, about 40% of the total daily dose was used in the evening and other doses relatively decreased compared to the basal doses in Group 1, while the ratio remained almost constant in Group 2.


There was no difference between the groups regarding hypoglycemic events. Sixty-five percent of patients in Group 1 and 66.6% in Group 2 had at least one hypoglycemic episode. Only 20% of patients in Group 1 had more than one hypoglycemic episode, while it was 45% in Group 2 (p=0.001). Hypoglycemia was mostly recorded to be related to incompliance with life style. None of the patients had severe hypoglycemia. Elderly patients were prone to hypoglycemia in Group 1; 70% of patients having hypoglycemia were above the age of 70 years. There was no age distribution in Group 2. Although it was not statistically significant, the mean hypoglycemic episode in patients of Group 1 was less than in patients of Group 2 (Figure 5). A median of 1,0 (0,0-2,0) hypoglycemic episode/patient was observed in Group 1 compared to 1.0 (0.0-6.0) hypoglycemic episode/patient in Group 2. There was no difference between the groups regarding nocturnal hypoglycemia. Hypoglycemic episodes did not correlate with A1C level or mean insulin dose.




Delta A1C correlated negatively with the age of the patients (p<0.0001, r=-0.316) and positively with the mean insulin dose administered (p=0.01, r=0.235). There was a correlation between delta FBG and the total daily insulin dose administered (p=0.015, r=0.221). There was no correlation between hypoglycemic events and the total daily insulin dose administered. In addition, duration of diabetes did not correlate with either A1C or blood glucose measurements. Multiple regression analysis revealed that only the basal A1C and the latest dose of insulin had an effect on AA1C.





This study demonstrated that treatment with insulin lispro premix 50/50 injected three times daily resulted in significantly better glycemic control compared to insulin aspart premix 70/30 injected two times daily without an increased risk of hypoglycemia.

In modern treatment algorithms for diabetes, insulin is located in the early phases of treatment periods even at the beginning. The ideal insulin regimen should include the agent that best mimics human physiology, can be practically applied and personalized. The gold standard treatment that best fits these rules is basal-bolus insulin regimen. Premixed insulins are a good alternative with their best practicality but lack in mimicking physiology. Application of premixed insulins three times daily was discovered to meet this deficit instead of standard application of two times daily. Insulin lispro premix 50/50 is a well-studied and a good model for three times daily applications. When compared with the gold standard basal-bolus insulin regimen, application of prandial insulin lispro premix 50/50 resulted in similar A1C decrease within 24 weeks of treatment period in a group of diabetic patients. Although fasting blood glucose levels and percentage of patients achieving target A1C levels were in favor of basal-bolus treatment, there was no difference in ability of improving postprandial blood glucose levels and similar risk of hypoglycemia was observed (9). Although noninferiority was not demonstrated, findings provide enough data to make it a good alternative to basal-bolus insulin regimen. Insulin lispro premix 50/50 injected three times daily was also compared with human insulin premix 70/30injected two times daily. Regarding mean, fasting and postprandial blood glucose levels, insulin lispro premix 50/50 provided better improvement. The decrease from baseline in A1C was significantly greater with insulin lispro premix 50/50 than with human insulin premix 70/30. There was no significant difference between the treatments regarding incidence of hypoglycemia (10).

Our study is first in comparing two different analog insulin regimens. Although the percentage of patients achieving target A1C level of below 6.5% was found to be similar between the treatment groups, insulin lispro premix 50/50 injected three times daily provided better glycemic control with an about 1.5% decrease in A1C levels compared to 0.54% decrease in insulin aspart premix 70/30 injected two times daily. This difference was found to be because of improvement in postprandial blood glucose levels since there was no difference in fasting glycemia between the treatment groups. Postprandial blood glucose control is sometimes more important than fasting glycemia since it was found to be strictly related to macrovascular complications and accepted as an independent cardiovascular risk factor irrespective of fasting blood glucose levels (11). Monnier et al. demonstrated that a true fasting state is 3 only three hours a day in a healthy person and the rest is either postprandial or postabsorbtive state (12). For this reason, any medication that is better in controlling postprandial glycemia will provide better prevention of cardiovascular risk in diabetics. However, postprandial blood glucose levels were above the goals in 31 % of diabetic patients who had normal fasting blood glucose levels (11). Ninety nine percent of patients with an A1C level of above 7% had postprandial blood glucose level of above 200 mg/dl (13). It was obviously shown in the DECODE Study that the control of postprandial glycemic state decreases the risk of cardiovascular disease (11). The results of this study show that insulin lispro premix 50/50 provide better postprandial glycemic control than insulin aspart premix 70/30. Similar results were also demonstrated in the study comparing it with human insulin premix 70/30. Insulin lispro premix 50/50 also provided similar postprandial glycemic control in comparison with basal-bolus insulin regimen. Although not in the scope of the goals of this study, this beneficial effect may provide improvement in cardiovascular risk in diabetics.

One of the main concerns in intensification of insulin regimen is the risk of hypoglycemia. It may deteriorate the health condition in diabetics and sometimes may increase the risk for mortality especially in critically ill patients and hide the benefits of the decrease in A1C levels (14). However, none of the studies showed an increased risk of hypoglycemia with insulin lispro premix 50/50 either compared to premix insulin 70/30 aspart or human insulin or basal-bolus insulin regimens. Thus, application of insulin lispro premix 50/50 three times daily for type 2 diabetic patients seems to be safe. Another aspect to be considered in insulin treatment is the total dose of insulin required to control glycemia. An increased risk of side effects including increase in body weight and risk of cancer parallel to increase in the daily dose of insulin is reported in studies (15,16). All patients in both groups in this study were started on insulin treatment with a dose of 0.5-0.6 units/kilogram body weight/day. But patients in insulin lispro premix 50/50 required significantly more insulin doses than patients in insulin aspart premix 70/30 group. On the other hand, the total daily insulin dose used during the study did not change compared to the basal doses in both groups. Unfortunately, body weight changes were not recorded properly, so that statistical analysis could not be possible. There were no reported side effects related to insulin treatment in any of the groups. There was no difference in the compliance of patients in the whole group considering use of medications or self-monitoring of blood glucose.

Potential limitations of the current study include the retrospective design and low number of patients. Comparison groups were not homogenous due to the retrospective manner. Patients were older and had longer duration of diabetes in the group of insulin aspart premix 70/30. The mean A1C levels at the start of insulin treatment was higher in the group of insulin lispro premix 50/50. This may create a bias in the comparison since relatively serious patients were included in this arm. Also the study design does not allow differentiating whether the decrease in A1C level was caused by the injection of insulin three times daily or the use of the molecule itself.

It will be interesting to add a third premix 70/30 injection at lunchtime, which will probably result in a lower mean blood glucose level. However, it cannot be certain that the risk of hypoglycemia will not increase due to higher doses of neutral protamin lispro part of insulin.

In conclusion, insulin lispro premix 50/50 provides better glycemic control without increasing the risk of hypoglycemia in type 2 diabetic patients compared to insulin aspart premix 70/30. Further prospective studies with larger number of patients are needed to better clarify the role of this kind of applications.


(1.) Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neil MC, Zinman B, Viberti G for the ADOPT Study Group. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med 2006;355:2427-43.

(2.) UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

(3.) Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

(4.) Ford ES, Li C, Little RR, Mokhad AH. Trends in A1C Concentrations Among U.S. Adults With Diagnosed Diabetes From 1999 to 2004. Diabetes Care 2008;31:102-4.

(5.) Mazurek JA, Hailpern SM, Goring T, Nordin C. Prevalence of Hemoglobin A1c Greater Than 6.5% and 7.0% among Hospitalized Patients without Known Diagnosis of Diabetes at an Urban Inner City Hospital. J Clin Endocrinol Metab 2010;95:1344-48.

(6.) Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR. Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.

(7.) Shestakova M, Bech OM, Momani MS. Study design and baseline characteristics of patients in the PRESENT study. Diab Res Clin Pract 2008;81:3-9.

(8.) Turner HE, Matthews DR. The use of fixed-mixture insulins in clinical practice. Eur J Clin Pharmacol 2000;56:19-25.

(9.) Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5.

(10.) Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res. 2004;36:188-93.

(11.) The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999;354:617-21.

(12.) Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 2000;30:3-11.

(13.) Erlinger TP et al. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes care 2001;24:1734-8.

(14.) Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med. 2007;10:2262-7.

(15.) Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting Insulin Therapy in Patients With Type 2 Diabetes: Effectiveness, Complications, and Resource Utilization. JAMA 1997; 278:1663-9.

(16.) Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44.

Hasan Aydin, Hulya Demir *, ibrahim Volkan Senkal **, Fevzi Firat Yalniz **, Ayse Ayrilmaz **

Yeditepe University Medical Faculty, Department of Endocrinology and Metabolism, istanbul, Turkey

* Yeditepe University Hospital, Diabetes Nurse, Department of Endocrinology and Metabolism, istanbul, Turkey

** Yeditepe University Medical Faculty, Department of Internal Medicine, istanbul, Turkey

Address for Correspondence: Hasan Aydin MD, Yeditepe University Medical Faculty, Department of Endocrinology and Metabolism, Istanbul, Turkey Tel.: +90 216 578 41 06 E-mail: Recevied: 05.09.2010 Accepted: 23.11.2010
Table 1. Baseline characteristics of the treatment groups

 Insulin Lispro Insulin Aspart p-value
 Premix 50/50 Premix 70/30

Gender (F/M) 28/32 28/34 0.886

Age (years) * 60 (24-84) 65 (39-90) 0.005

Duration of diabetes
 (years) * 8.0 (0-36) 9.5 (0-37) 0.04

BMI (kg/[m.sup.2]) * 30 (27-36) 29 (26-36) 0.814

Complications (%)
 Any microvascular 10 12 0,871
 Any macrovascular 5 6 0.869

Co-existing disease (%)
 Hypertension 40 58 0.201
 Hyperlipidemia 68 76 0.334

Table 2. Major findings of the study groups

 Insulin Lispro Insulin Aspart p-value
 Premix 50/50 Premix 70/30

Change in
A1C (%)
 Basal A1C 8.9 [+ or -] 1.7 7.9 [+ or -] 1.2 0.002
 Last A1C 7.3 [+ or -] 1.0 7.1 [+ or -] 0.9 ns
 [DELTA] A1C 1.61 [+ or -] 1.47 0.87 [+ or -] 0.93 0.0006

Change in FBG
 Basal FBG 193.4 [+ or -] 66.7 167.8 [+ or -] 53.0 ns
 Last FBG 138.1 [+ or -] 24.8 129.0 [+ or -] 27.9 0.008
 [DELTA] FBG 30.3 [+ or -] 45.9 59.5 [+ or -] 64.6 0.005

Total daily
insulin dose
 Basal dose 60.9 [+ or -] 23.2 42.4 [+ or -] 16.6 <0.0001
 Last dose 59.8 [+ or -] 28.3 47.1 [+ or -] 21.9 0.002
 Mean dose 59.0 [+ or -] 22.3 44.9 [+ or -] 16.6 0.0003

 Cumulative 0.91 [+ or -] 0.86 1.53 [+ or -] 1.59 ns
 Nocturnal 0.26 [+ or -] 0.48 0.43 [+ or -] 0.69 ns
COPYRIGHT 2010 Galenos Yayincilik
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Article/Orijinal Makale
Author:Aydin, Hasan; Demir, Hulya; Senkal, Ibrahim Volkan; Yalniz, Fevzi Firat; Ayrilmaz, Ayse
Publication:Turkish Journal of Endocrinology and Metabolism
Article Type:Report
Geographic Code:7TURK
Date:Sep 1, 2010
Previous Article:Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma (PPAR[gamma]) and components of metabolic syndrome/...
Next Article:Physician adherence to the SEMT guidelines for the management of type 2 diabetes in Turkey: ADMIRE study/Tip 2 diyabet tedavisinde hekimlerin...

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters